Synthesis and characterization of a theranostic vascular disrupting agent for in vivo MR imaging

Bioconjugate Chemistry

Volumn 22, Issue 5, 2011, Pages 879-886

  Kalber, Tammy L ^a   Kamaly, Nazila ^a,b   Higham, Stephanie A ^a   Pugh, John A ^c   Bunch, Josephine ^c,d   McLeod, Cameron W ^c   Miller, Andrew D ^b   Bell, Jimmy D ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CELL PROLIFERATION; DIAGNOSIS; GADOLINIUM COMPOUNDS; HISTOLOGY; MAGNETIC RESONANCE IMAGING; TUMORS;

BINDING AGENT; CELL SHAPES; EX-VIVO; GADOLINIA; IN-VITRO; IN-VIVO; MR IMAGING; SYNTHESIS AND CHARACTERIZATIONS; THERANOSTICS; VASCULAR DISRUPTING AGENTS;

CELL DEATH;

COLCHICINE DERIVATIVE; GADOTERIC ACID; GADOTERIC ACID COLCHICINIC ACID CONJUGATE; TUBULIN; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL DIVISION; CELL SHAPE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CARCINOMA; PHARMACODYNAMICS; TISSUE DISTRIBUTION; TUMOR NECROSIS; TUMOR XENOGRAFT;

EID: 80052995735     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc100329t     Document Type: Article

References (43)

1. Vaupel, P., Kallinowski, F., and Okunieff, P. (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human. tumors: a review. Cancer Res. 49, 6449-6465. (Pubitemid 20008770)
2. Denekamp, J. (1993) Review article: angiogenesis, neovascular. proliferation and vascular pathophysiology as targets for cancer therapy. Br. J. Radiol. 66, 181-196. (Pubitemid 23096969)
3. Carmeliet, P., and Jain, R. K. (2000) Angiogenesis in cancer and. other diseases. Nature 407, 249-257.
4. Bergers, G., and Benjamin, L. E. (2003) Tumorigenesis and the. angiogenic switch. Nat. Rev. Cancer 3, 401-410.
5. Siemann, D. W., Chaplin, D. J., and Horsman, M. R. (2004). Vascular-targeting therapies for treatment of malignant disease. Cancer. 100, 2491-2499. (Pubitemid 38715753)
6. Siemann, D. W., Bibby, M. C., Dark, G. G., Dicker, A. P., Eskens,. F. A., Horsman, M. R., Marme, D., and Lorusso, P. M. (2005). Differentiation and definition of vascular-targeted therapies. Clin. Cancer. Res. 11, 416-420. (Pubitemid 40116863)
7. Micheletti, G., Poli, M., Borsotti, P., Martinelli, M., Imberti, B.,. Taraboletti, G., and Giavazzi, R. (2003) Vascular-targeting activity of. ZD6126, a novel tubulin-binding agent. Cancer Res. 63, 1534-1537. (Pubitemid 36373640)
8. Horsman, M. R., Ehrnrooth, E., Ladekarl, M., and Overgaard, J. (1998) The effect of combretastatin A-4 disodium phosphate in a C3H. mouse mammary carcinoma and a variety of murine spontaneous. tumors. Int. J. Radiat. Oncol. Biol. Phys. 42, 895-898. (Pubitemid 28559438)
9. Blakey, D. C., Westwood, F. R., Walker, M., Hughes, G. D.,. Davis, P. D., Ashton, S. E., and Ryan, A. J. (2002) Antitumor activity of. the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin. Cancer Res. 8, 1974-1983. (Pubitemid 34633761)
10. Tozer, G. M., Prise, V. E., Wilson, J., Locke, R. J., Vojnovic, B.,. Stratford, M. R., Dennis, M. F., and Chaplin, D. J. (1999) Combretastatin. A-4 phosphate as a tumor vascular-targeting agent: early effects in. tumors and normal tissues. Cancer Res. 59, 1626-1634. (Pubitemid 29160136)
11. Siemann, D. W., and Horsman, M. R. (2002) Enhancement of. radiation therapy by vascular targeting agents. Curr. Opin. Invest. Drugs. 3, 1660-1665. (Pubitemid 36266744)
12. Dark, G. G., Hill, S. A., Prise, V. E., Tozer, G. M., Pettit, G. R., and Chaplin, D. J. (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57, 1829-1834. (Pubitemid 27209705)
13. Dowlati, A., Robertson, K., Cooney, M., Petros, W. P., Stratford, M., Jesberger, J., Rafie, N., Overmoyer, B., Makkar, V., Stambler, B., Taylor, A., Waas, J., Lewin, J. S., McCrae, K. R., and Remick, S. C. (2002) A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 62, 3408-3416. (Pubitemid 34651387)
14. Beauregard, D. A., Hill, S. A., Chaplin, D. J., and Brindle, K. M. (2001) The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res. 61, 6811-6815. (Pubitemid 32896505)
15. Maxwell, R. J., Wilson, J., Prise, V. E., Vojnovic, B., Rustin, G. J., Lodge, M. A., and Tozer, G. M. (2002) Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed. 15, 89-98. (Pubitemid 34213398)
16. Evelhoch, J. L., LoRusso, P. M., He, Z., DelProposto, Z., Polin, L., Corbett, T. H., Langmuir, P., Wheeler, C., Stone, A., Leadbetter, J., Ryan, A. J., Blakey, D. C., and Waterton, J. C. (2004) Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin. Cancer Res. 10, 3650-3657. (Pubitemid 38697598)
17. Galbraith, S. M., Maxwell, R. J., Lodge, M. A., Tozer, G. M., Wilson, J., Taylor, N. J., Stirling, J. J., Sena, L., Padhani, A. R., and Rustin, G. J. (2003) Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J. Clin. Oncol. 21, 2831-2842. (Pubitemid 46621830)
18. Robinson, S. P., McIntyre, D. J., Checkley, D., Tessier, J. J., Howe, F. A., Griffiths, J. R., Ashton, S. E., Ryan, A. J., Blakey, D. C., and Waterton, J. C. (2003) Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br. J. Cancer 88, 1592-1597. (Pubitemid 36713788)
19. Robinson, S. P., Kalber, T. L., Howe, F. A., McIntyre, D. J., Griffiths, J. R., Blakey, D. C., Whittaker, L., Ryan, A. J., and Waterton, J. C. (2005) Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging. Neoplasia 7, 466-474. (Pubitemid 40791866)
20. Thoeny, H. C., De Keyzer, F., Chen, F., Vandecaveye, V., Verbeken, E. K., Ahmed, B., Sun, X., Ni, Y., Bosmans, H., Hermans, R., van Oosterom, A., Marchal, G., and Landuyt, W. (2005) Diffusionweighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration. Neoplasia 7, 779-787.
21. Thoeny, H. C., De Keyzer, F., Chen, F., Ni, Y., Landuyt, W., Verbeken, E. K., Bosmans, H., Marchal, G., and Hermans, R. (2005)Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology 234, 756-764. (Pubitemid 40250819)
22. Wang, H., Sun, X., Chen, F., De Keyzer, F., Yu, J., Landuyt, W., Vandecaveye, V., Peeters, R., Bosmans, H., Hermans, R., Marchal, G., and Ni, Y. (2009) Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology. Invest. Radiol. 44, 44-53.
23. Ni, Y., Bormans, G., Chen, F., Verbruggen, A., and Marchal, G. (2005) Necrosis avid contrast agents: functional similarity versus structural diversity. Invest. Radiol. 40, 526-535. (Pubitemid 41040690)
24. Madhu, B., Waterton, J. C., Griffiths, J. R., Ryan, A. J., and Robinson, S. P. (2006) The response of RIF-1 fibrosarcomas to the vascular-disrupting agent ZD6126 assessed by in vivo and ex vivo 1H magnetic resonance spectroscopy. Neoplasia 8, 560-567. (Pubitemid 44061311)
25. Zhao, M., Beauregard, D. A., Loizou, L., Davletov, B., and Brindle, K. M. (2001) Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat. Med. 7, 1241-1244. (Pubitemid 33063780)
26. Satpati, D., Korde, A., Pandey, U., Dami, P., Banerjee, S., and Venkatesh, M. (2006) Synthesis and evaluation of 90Y-DOTA-Colchicine conjugate in murine fibrosarcoma model. J. Labelled Compd. Radiopharm. 49, 951-958. (Pubitemid 44831280)
27. Clark, J. I., and Garland, D. (1978) Fluorescein colchicine. Synthesis, purification, and biological activity. J. Cell Biol. 76, 619-627. (Pubitemid 8295904)
28. Bagnato, J. D., Eilers, A. L., Horton, R. A., and Grissom, C. B. (2004) Synthesis and characterization of a cobalamin-colchicine conjugate as a novel tumor-targeted cytotoxin. J. Org. Chem. 69, 8987-8996. (Pubitemid 40004017)
29. van Rossenberg, S. M., Sliedregt-Bol, K. M., Koning, G., van den Elst, H., van Berkel, T. J., van Boom, J. H., van der Marel, G. A., and Biessen, E. A. (2003) Improvement of hepatocyte-specific gene expression by a targeted colchicine prodrug. ChemBioChem 4, 633-639. (Pubitemid 36896986)
30. Zareneyrizi, F., Yang, D. J., Oh, C. S., Ilgan, S., Yu, D. F., Tansey, W., Liu, C. W., Kim, E. E., and Podoloff, D. A. (1999) Synthesis of [99mTc]ethylenedicysteine-colchicine for evaluation of antiangiogenic effect. Anticancer Drugs 10, 685-692. (Pubitemid 29450211)
31. Korde, A., Satpati, D., Mathur, A., Mallia, M., Banerjee, S., Kothari, K., Sarma, H. D., Choudhari, P., and Venkatesh, M. (2006) 99mTc-labeling of colchicine using [99mTc(CO)3(H2O)3]+ and [99mTc triple bond N]2+ core for the preparation of potential tumor-targeting agents. Bioorg. Med. Chem. 14, 793-799.
32. Efthimiadou, E. K., Katsarou, M. E., Fardis, M., Zikos, C., Pitsinos, E. N., Kazantzis, A., Leondiadis, L., Sagnou, M., and Vourloumis, D. (2008) Synthesis and characterization of novel natural product-Gd(III) MRI contrast agent conjugates. Bioorg. Med. Chem. Lett. 18, 6058-6061.
33. Barge, A., Cravotto, G., Gianolio, E., and Fedeli, F. (2006) How to determine free Gd and free ligand in solution of Gd chelates. A technical note. Contrast Media Mol. Imaging 1, 184-188.
34. Rasband, W. S. (1997-2008) ImageJ, U.S. National Institutes of Health, Bethesda, MD, http://rsb.info.nih.gov/ij/.
35. Ahmed, B., Van Eijk, L. I., Bouma-Ter Steege, J. C., Van Der Schaft, D. W., Van Esch, A. M., Joosten-Achjanie, S. R., Lambin, P., Landuyt, W., and Griffioen, A. W. (2003) Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity. Int. J. Cancer 105, 20-25. (Pubitemid 36418480)
36. Davis, P. D., Dougherty, G. J., Blakey, D. C., Galbraith, S. M., Tozer, G. M., Holder, A. L., Naylor, M. A., Nolan, J., Stratford, M. R., Chaplin, D. J., and Hill, S. A. (2002) ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res. 62, 7247-7253. (Pubitemid 36025246)
37. Galbraith, S. M., Chaplin, D. J., Lee, F., Stratford, M. R., Locke, R. J., Vojnovic, B., and Tozer, G. M. (2001) Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. 21, 93-102. (Pubitemid 32267629)
38. Lin, C. M., Ho, H. H., Pettit, G. R., and Hamel, E. (1989) Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 28, 6984-6991. (Pubitemid 19219888)
39. McGown, A. T., and Fox, B. W. (1989) Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile. Anti-Cancer Drug Des. 3, 249-254. (Pubitemid 19100902)
40. Tozer, G. M., Kanthou, C., and Baguley, B. C. (2005) Disrupting tumour blood vessels. Nat. Rev. Cancer 5, 423-435. (Pubitemid 40791485)
41. Partridge, E. A., D'Souza, R. A., Lenz, E. M., Smith, S. M., Clarkson-Jones, J., and Roberts, D. W. (2008) Disposition and metabolism of the colchicine derivative [14C]-ZD6126 in rat and dog. Xenobiotica 38, 399-421. (Pubitemid 351380286)
42. D'Souza, R. A., Partridge, E. A., Roberts, D. W., Ashton, S., Ryan, A., Patterson, A. B., Wilson, Z., and Thurrell, C. C. (2007) Distribution of radioactivity and metabolite profiling in tumour and plasma following intravenous administration of a colchicine derivative (14C-ZD6126) to tumour-bearing mice. Xenobiotica 37, 328-340. (Pubitemid 46439677)
43. McIntyre, D. J., Robinson, S. P., Howe, F. A., Griffiths, J. R., Ryan, A. J., Blakey, D. C., Peers, I. S., and Waterton, J. C. (2004) Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-O-phosphate), reduces perfusion for at least 96 h in the GH3 prolactinoma rat tumor model. Neoplasia 6, 150-157. (Pubitemid 38544603)